 |
인쇄하기
취소
|
Sanofi “Bone cancer cure” development stopped
Due to safety --- side effects reported
(medical pharmaceutical news)
Sanofi stopped all clinical trials and approval process of Fedratinib for rare bone cancer due to safety issue.
This decision was made due to the reports of side effects on the disabled Wernicke’s encephalopathy in the recent clinical trial of Fedratinib.
Fedratinib which is JAK2 inhibitor was on Phase 3 clinical tr...
(medical pharmaceutical news)
Sanofi stopped all clinical trials and approval process of Fedratinib for rare bone cancer due to safety issue.
This decision was made due to the reports of side effects on the disabled Wernicke’s encephalopathy in the recent clinical trial of Fedratinib.
Fedratinib which is JAK2 inhibitor was on Phase 3 clinical tr...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.